Literature DB >> 15715615

Preemptive effect of intravenous ketamine in the rat: concordance between pain behavior and spinal fos-like immunoreactivity.

I-H Lee1, I-O Lee.   

Abstract

BACKGROUND: The purpose of this study was to compare behavioral antinociceptive responses with spinal fos-like immunoreactivity (FLI) for a intravenous ketamine injection between pre vs. postformalin administration in rats.
METHODS: Sprague-Dawley rats (250-300 g) were prepared to receive either saline or ketamine. All rats were randomly divided into three groups: control, pretreatment and post-treatment group. Formalin (5%) 100 microl was injected into the hindpaw. Pain related behavior and FLI in the lumbar spinal cord was examined.
RESULTS: Flinches of phase 2 were 239.3 (22,8), 118.6 (7,5) (P < 0.05 vs. control and post-treatment group), and 186.7 (16,6) in the control, pre and, post-treatment groups, respectively. Fos-like immunoreactivity expression was significantly correlated with phase 2 flinching behavior (P < 0.001).
CONCLUSION: Pretreatment with intravenous ketamine inhibits inflammatory pain behavior and FLI expression following a formalin injection in rats, suggesting that pretreatment of ketamine plays an important role in preemptive analgesia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15715615     DOI: 10.1111/j.1399-6576.2004.00568.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  Fluorocitrate, an inhibitor of glial metabolism, inhibits the up-regulation of NOS expression, activity and NO production in the spinal cord induced by formalin test in rats.

Authors:  Xiao-Cai Sun; Wei-Na Chen; Shu-Qin Li; Jin-Song Cai; Wen-Bin Li; Xiao-Hui Xian; Yu-Yan Hu; Min Zhang; Qing-Jun Li
Journal:  Neurochem Res       Date:  2008-07-16       Impact factor: 3.996

2.  Preemptive application of QX-314 attenuates trigeminal neuropathic mechanical allodynia in rats.

Authors:  Jeong-Ho Yoon; Jo-Young Son; Min-Ji Kim; Song-Hee Kang; Jin-Sook Ju; Yong-Chul Bae; Dong-Kuk Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.